Trial Profile
A Phase II Study of Ramucirumab for Advanced, Pre-Treated Biliary Cancers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary)
- Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 07 Jul 2022 Status changed from active, no longer recruiting to completed.
- 12 Mar 2022 Results published in the Clinical Cancer Research.
- 29 Jan 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.